Lazard Asset Management LLC Acquires 162,417 Shares of Immatics (NASDAQ:IMTX)

Lazard Asset Management LLC raised its holdings in shares of Immatics (NASDAQ:IMTX - Free Report) by 186,686.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 162,504 shares of the company's stock after acquiring an additional 162,417 shares during the quarter. Lazard Asset Management LLC owned about 0.14% of Immatics worth $1,155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE raised its holdings in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Virtus ETF Advisers LLC increased its holdings in shares of Immatics by 34.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after purchasing an additional 2,479 shares during the period. Guggenheim Capital LLC bought a new position in shares of Immatics in the fourth quarter worth $101,000. Forefront Analytics LLC increased its holdings in shares of Immatics by 42.3% in the fourth quarter. Forefront Analytics LLC now owns 15,911 shares of the company's stock worth $113,000 after purchasing an additional 4,731 shares during the period. Finally, Graham Capital Management L.P. bought a new position in shares of Immatics in the fourth quarter worth $130,000. Institutional investors own 64.41% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IMTX shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. Wall Street Zen lowered shares of Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Immatics Price Performance

NASDAQ IMTX traded down $0.09 during trading on Friday, hitting $5.11. 375,092 shares of the company's stock traded hands, compared to its average volume of 653,124. The stock has a fifty day moving average of $4.52 and a two-hundred day moving average of $5.68. Immatics has a 12-month low of $3.30 and a 12-month high of $13.77. The firm has a market cap of $621.12 million, a P/E ratio of -7.74 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $20.12 million during the quarter, compared to analyst estimates of $14.92 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. As a group, analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.